Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17892426 | 1.00 | BTK (0.48) | BTKTNK2 | |
| SCHEMBL19660351 | 1.00 | BTK (0.48) | BTKTNK2 | |
| SCHEMBL17893241 | 1.00 | BTK (0.48) | BTKTNK2 | |
| SCHEMBL17893361 | 0.89 | BTK (0.40) | BTKTNK2 | |
| SCHEMBL1129637 | 0.82 | TNK2 (0.63) | TNK2 | |
| SCHEMBL1129633 | 0.82 | TNK2 (0.63) | TNK2 | |
| SCHEMBL19737826 | 0.81 | TNK2 (0.50) | BTKTNK2 | |
| SCHEMBL17893377 | 0.79 | TNK2 (0.47) | BTKTNK2 | |
| SCHEMBL17899635 | 0.79 | TNK2 (0.46) | BTKTNK2 | |
| SCHEMBL17893138 | 0.77 | BTK (0.47) | BTKTNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3240572-B1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3240546-B1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-3240546-B1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2020-10-21 | — | — | EP | disclosed |
| US-10208047-B2 | Tertiary alcohol imidazopyrazine BTK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10087188-B2 | Benzamide imidazopyrazine Btk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-10-02 | — | — | US | disclosed |
| US-20170362242-A1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170342076-A1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-11-30 | — | — | US | disclosed |
| EP-3240546-A1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3240572-A1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016109222-A1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016109223-A1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362242-A1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | BTK, SYK, ABL1 | BTK 1/4885TNK2 206/4885 |
| US-10087188-B2 | Benzamide imidazopyrazine Btk inhibitors | BTK, SYK, ABL1 | BTK 1/4885TNK2 206/4885 |
| US-10208047-B2 | Tertiary alcohol imidazopyrazine BTK inhibitors | BTK, SYK, ABL1 | BTK 1/4885TNK2 343/4885 |
| US-20170342076-A1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | BTK, SYK, ABL1 | BTK 1/4885TNK2 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.